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Abstract From the conventional Bird’s eye, cancer ini-
tiation and metastasis are generally intended to be under-
stood beneath the light of classical clonal genetic,
epigenetic and cancer stem cell model. But inspite decades
of investigation, molecular biology has shown hard success
to give Eagle’s eye in unraveling the riddle of cancer. And
it seems, tiring Tom runs in vague behind naughty Jerry.
Keywords Molecular biology  Cancer  Epigenetics 
Cancer stem cell  Clonal expansion
Introduction
‘‘…it is necessary to periodically subject to the
deepest revision the principles, which were recog-
nized as final and were no longer discussed’’.
Louis de Broglie
Molecular biology is materialistic in underlying belief
[1], where biological organization is determined by linear
relationship among DNA, RNA and protein [2]. But there
are several evidences available that contradict this linear
central dogma of life. Goldschmidt [3] found that at a
certain developmental stage, if Drosophila embryos are
exposed for short duration to high temperature, X-rays, or
other factors; there may be phenotypic alterations that
mimic or copy the kind of changes produced by gene
mutations and sometimes these changes may be heritable
indicating that they are accompanied by genetic mutations.
He termed these phenotypic changes which can cause
mutations in the encoding genome as ‘phenocopy’ and this
phenomenon is contrary to the linear pattern of DNA–
RNA–Protein [1]. Again, the occurrence of adaptive
mutations has challenged the neo-Darwinian principle that
selection for advantageous mutations directs the evolu-
tionary change where mutations occur randomly [4]. Cairns
et al. [5] reported that when the mutant phenotype has clear
selective advantage, the specific mutations take place at a
much higher rate in bacteria. These adaptive mutations
have since been reported in many bacteria and eukaryotes
[6–10].
Moreover, the notion that DNA is the complete hered-
itary determinant is under question by several investiga-
tions. DNA polymerase, a nano-biomotor, is subjected to
about 3 9 105 computational steps for every DNA base
that the motor reads. Each of the internal microscopic
states of the protein can store information, and these higher
information storage densities cannot be stored in DNA
alone [11]. C-value paradox shows that organizational
complexity is not determined by the DNA sequence [12],
as a simple microorganism may carry larger DNA
sequence than complex human. Even the form of an
organism may evolve in absence of corresponding molec-
ular evolution in DNA [13, 14]. Thus, the DNA is merely
able to transfer the information for the shape of the pro-
teins, not to transfer the information necessary to organize
the proteins inside the cell. Experiments showed that
Tetrahymena pyriformis cells and T. vorax microstomes
maintain similar morphology with different proteins, while
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T. vorax microstomes and T. vorax macrostomes maintain
different morphologies with similar proteins and the cel-
lular configuration is not decided by the proteins they
consist of [15, 16]. Apparently, the mechanisms behind cell
(supra-cellular as well) organization and morphogenesis,
thereby seem to be very difficult to describe in terms of a
conventional molecular biological frame [17].
Cancer is not a regular type of disease rather a group of
disease [18], which could be viewed as an aberrant organ
[19] that is characterized through the process of tumori-
genesis, whereby cells accumulate mutations in oncogenes
or tumor suppressor genes that allow chromosomal aber-
rations, genomic and proteomic instabilities [20], and
ultimately result into abnormal proliferation and differen-
tiation [21]. The organization of cells takes place at dif-
ferent levels from molecules to organelles that again
organize to form the full cell, and cell organelles are
shaped precisely after the needs of the specific type of cell,
e.g., endoplasmic reticule, the golgi apparatus, the vesicle,
cell membrane systems, and mitochondrion, that take their
shape after the specific type of cell [2]. And cancer cells
reorganizes these organelles [22] indicating that basic
organizational pattern of the living system may be involved
in cancer initiation and progression. Also there are several
hints pointing that cancer evolution ascertains non-linear-
ity, geometric alterations in biomolecular arrangement.
There are characteristic differences in the nuclear archi-
tectures of cancer cells, compared with the normal cells
(Fig. 1). Cancer also accelerates the aging process [23] and
disrupts the orderliness of the body. These evidences could
be the account for both spatial and temporal disorder in
cancer.
In molecular biology, it is the common thought that
activation of oncogenes or inactivation of tumor suppressor
genes occurs through a point mutation, a deletion or a
translocation inside the genome [25]. Clonal expansion
model, epigenetic alterations and cancer stem cell model
(Fig. 2) have tried to explain cancer initiation and metas-
tasis from the classical view-point. However, our approach
is aimed for a brief verification of these existing views
from a closer look.
Clonal expansion
There are several genes responsible for controlled growth
in human body. Errors in these genes due to germline
defects, intrinsic replication errors and environmental
mutagens are very general. With age-dependent growth
Fig. 1 Nuclear structure in
a normal cells and b cancer
cells [24]
Fig. 2 Unified classical approach for cancer initiation
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control, loosen and neoplastic cells may appear, so that a
linear multistage model was used to explain the origin of
cancer [26, 27]. Mutations in several oncogenes, tumor
suppressor genes (TSGs), and genomic stability genes
occur in cancer [28]. According to the clonal genetic
model, carcinogenesis is a multistage process [29–31]
which involves initiation (due to inheritance, environ-
ment and spontaneous errors), promotion (due to muta-
tion in oncogenes and tumor suppressor genes),
progression (uncontrolled growth) and conversion into
neoplastic phenotype (cancer) that can metastasize
[29, 32].
A gene increases the response to growth stimulation
by a growth factor, inhibits the ability of a stem cell to
terminally differentiate or become apoptotic with an
initiating mutation, and promoters such as epidermal
growth factor (EGF) might induce proliferation selec-
tively in those initiated cells [29]. But there is evidence
of carcinogenesis, due to over expression of promoters
like EGF where no initial mutation occurred [33]. Again,
it is not necessary for oncogenes to perform strictly at
the promotional phase of carcinogenesis. It was reported
that codon 12 mutations of H-ras oncogene in rat
mammary and esophagus tumors were present prior to
the tumor formation [34, 35]. Urban et al. [36] showed
that K-ras mutations may occur after neoplastic con-
version. These findings certainly disrupt the linearity of
clonal genetic model. Moreover, most cancer cells are
aneuploid and missegregation of chromosomes occur
frequently during mitosis, and spindle checkpoint acts as
the main cell cycle control mechanism that prohibits
chromosomal instability, in normal condition [37]. In the
absence of chromosomal instability deletion or altera-
tions in tumor suppressor genes will lead to apoptosis
[32]. But mutation or deletion of a major tumor sup-
pressor gene RB should occur in G1 phase in order to
continue deregulated cell cycle and tumor suppressor
gene CDKN2 is also found deleted in G1 phase of cell
cycle [38], while chromosome segregation occurs in
mitotis and chromosomal instability might initiate car-
cinogenesis [39]. So it seems, the process of cancer
initiation might be non-linear.
Clonal selection model is a mere assumption [32] which
is effective when cells are known in terms of one mutated
or altered oncogene at a time. But the fact is, a large
number of genetic alterations occur within the same gen-
ome to create genetic instability [40]. There are a number
of models to explain this complex dynamic process
involving caretaker and gatekeeper mutations [39, 41, 42].
So, in the context of cancer cells, this linear clonal
expansion or clonal genetic model may be said to be quite
obsolete [43] if not immersed with a modern holistic
approach for cancer initiation.
Classical epigenetic model
Epigenetics defines the heritable alterations in gene
expression without changes in DNA sequence. These
alterations include DNA methylation, histone modifica-
tions, packaging of DNA around nucleosomes, chromatin
folding and attachment to the nuclear matrix [44]. Global
DNA hypomethylation, local hypermethylation in pro-
moter region of tumor suppressor genes, alterations in
chromatin remodeling, loss of gene imprinting (LOI) are
the epigenetic processes which may precede genetic
mutations and genomic instability in tumorigenesis [45,
46]. These preceding epigenetic changes in early stages of
tumorigenesis in pre-malignant cells of tumor, e.g., lung,
colon and prostate tumors might direct the subsequent
genetic alterations and help in tumor progression [47–52].
Epigenetics plays a major role in the development and
cellular differentiation of an organism, and the alterations
in epigenetic processes cause inappropriate gene silencing
followed by tumor formation [53, 54].
There is evidence for genetic regulation of epigenetic
phenomena. Alterations in this epigenetic gene expression
pattern will cause epigenomic instability. DNA methyl-
transferase (DNMTs), methyl-binding protein (MBDs),
histone acetylase (HATs), histone deacetylase (HDACs),
histone methylase (HMTs), histone demethylase etc. are
epigenetic genes found inside the genome. There may be
both germline (high penetrance or low to medium pene-
trance) and somatic changes in these genes which cause
epigenomic alterations in tumorigenesis. For instance, four
member of DNMT family: DNMT1, TRDMT1, DNMT3A
and DNMT3B are responsible for transferring methyl
group to cytosine residues in CpG islands [55]. Germline
single nucleotide polymorphisms (SNPs) in DNMT3B
have been reported to increase the risk of cancer. One SNP
(-149C [ T) may increase the risk of breast cancer [56],
two SNP (-283T [ C and -579G [ T) may increase the
risk of lung adeno-carcinoma [57]. DNMT1 inactivation
may be associated with tumorigenesis as 2 of 29 colorectal
cancer patients showed somatic mutation in DNMT1 [58].
Epigenetic silencing of SFRP gene activates Wnt pathway
in early colonic neoplasia. DNMT genes were deleted in
colon cancer cell line HCT116. Despite activated b-catenin
expression, the cells had shown down regulation of Wnt
pathway and apoptosis, because the deletion led to SFRP
re-expression through promoter demethylation [59]. This
certainly proves the role of epigenetic genes in tumori-
genesis which may act as oncogenes or tumor suppressor
genes. But the underlying processes causing alterations in
epigenetic genes is mostly unknown [55].
Recently, it has been found that small, single stranded
micro-RNAs (miRNAs) have regulatory role in gene
expression by interfering with mRNAs and also
Oncol Rev (2011) 5:215–222 217
123
participates in metabolism, differentiation, cell cycle
regulation, development etc. [60, 61]. MiRNAs show
similar regulatory mechanisms like protein-coding genes
[62]. Most of these miRNAs e.g., miR-1 and miR-34b/c
in colorectal cancer, miR-9 in breast cancer, let-7 in
colorectal, prostate, lung, breast cancers and hepatocel-
lular carcinoma are epigenetically regulated [63–67].
But a small group of miRNAs called epi-miRNA seems
to regulate epigenetic genes such as miR-148a/b targets
DNMT3b in cervical cancer [68, 69], miR-449a targets
HDAC1 in prostate cancer [70]. There is also evidence
for gene introns to produce mi-RNA which are named as
intron-derived miRNA (Id-miRNAs), and these Id-miR-
NAs can regulate gene expression through RNA inter-
ference. Altered Id-miRNAs due to changes in intron
sequence can cause diseases such as myotonic dystrophy
and fragile X syndrome [71]. As large arena of detailed
miRNAs and Id-miRNAs function is yet to be eluci-
dated, these molecules may have obvious relation with
genetic and epigenetic changes leading to tumorigenesis.
There are reports like, miRNA let-7 acts as tumor sup-
pressor in lung cancer while it targets oncogene RAS and
miR-21 acts as oncogene in several neoplasm while
targeting tumor suppressor PTEN1 and PDCD4 [72].
Gene function competency depends on both faithful
transcription of protein-coding genes and controlled
spatial and temporal regulation which involves epige-
netics [73]. MiRNAs, epi-miRNAs and Id-miRNAs have
created new complexities in unraveling the mystery
behind cancer initiation.
Cancer stem cells
Tumor sample from different patients and even cells within
the same tumor shows significant discrepancy in mor-
phology, proliferative potential, ability for metastasis and
invasion as a reflection of variation in genetic and epige-
netic aberrations [74]. The ability to form a tumor has been
found to be limited within very small proportion of cancer
cells. Experiment with neuroblastoma, ovarian and lung
cancer had shown that only 1 out of 1–5,000 cancer cells
could form colony in soft agar [19]. Malignant cervical
epithelial cells express proteins such as nanog, nucleoste-
min, and musashi1 which are also highly expressed in
embryonic stem cells [75]. Widespread potential for pro-
liferation is characteristic of both normal stem cells and
tumorigenic cells which make them capable of forming
normal and abnormal organs, respectively [21]. From this
point of view, we can say cancer is an abnormal organ that
exhibits false impression of normal tissue development,
where growth is driven by the stem cell apex [76]. Stem
cells give rise to off-springs which can either retain
stemness similar to the parent through self renewing
capacity [19], or can go to differentiation pathway through
negative feedback loops (epigenetic switching) repressing
the self renewal genes and produce phenotypically diverse
transit-amplifying progenitors [77]. A cancer cell carrying
these similar properties is termed as cancer stem cell that
subsequently produces new cancer stem cells and non-self-
renewal progenies which form the bulk of tumor. These
non-self-renewal progenies are reactive to therapy while
stem cells escape the therapeutic effect and may form
tumor anew [46, 78].
Several cancer gene pathways such as Bmi-1, Wnt,
Sonic hedgehog (Shh), and Notch may show involvement
in the regulation of normal stem cell development, and
these self renewal genes were primarily recognized as
oncogenes for their role in tumorigenesis [19, 79, 80]. For
example, Wnt pathway might have a role in hematopoietic
stem cells (HSCs) self renewal [79] as Wnt proteins are
found in bone marrow during normal development [81]. In
canonical Wnt pathway, binding of Wnt protein with
transmembrane receptor protein frizzled results in inacti-
vation of b-catenin degradation complex that comprises
GSK3-beta, APC and AXIN. Consequently, stabilized b-
catenin translocates to the nucleus and activates TCF
transcription factor which activates proto-oncogene
CCND1 and C-MYC. In the absence of Wnt signal, b-
catenin is tainted by the degradation complex. Disregulated
Wnt signaling due to mutations in genes that encode pro-
teins involved in this pathway can cause tumor formation
[82]. Aberrant Wnt signaling was seen in various cancer
samples such as leukemia, colon cancer, colorectal cancer
which might contribute to the self renewal of cancer stem
cells [83]. Ability for differentiation and self renewal are
the basic criteria of stem cells [74] that need to be balanced
in order to maintain a homeostatic stem cell pool [44], and
normal tissue organization is determined through tight
regulation of stem cell expansion [84, 85]. Morrison et al.
[86] have shown multigenic regulation of hematopoietic
stem cell (HSC) number in mouse model. Different ways
such as oncogenic mutation that causes aberrant expansion
of normal stem cell, gaining self renewal capability
through oncogene activation that subverts the negative
feedback loop in transit-amplifying progenitors, or multiple
mutations in differentiated cells allowing de-differentiation
can originate cancer stem cell [18, 44]. Aberrant epigenetic
switching may transform normal cells into tumorigenic
cells [62]. In nude mice, IL6/NF-kB/LIN28B/let-7 positive
feedback loop is required to maintain the self renewing
capacity of cancer stem cells which were epigenetically
transformed due to inflammation [66]. Again through
OCT4/SOX2/C-MYC/KLF4 positive feedback loop, adult
fibroblast cells can be reprogrammed into stem cell like
state [62].
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Stem cell microenvironments also have vital role in
maintaining self renewal capacity and determining differ-
entiation pattern. Tissue architecture can be maintained
even in the presence of transformed cells by a normal
microenvironment, while a mutated cell can be triggered to
form tumor by aberrant microenvironment [87]. Wnt
ligands can be produced from both HSCs and microenvi-
ronment [88]. Also there is evidence against cancer stem
cell model. Each cancer cell showed stemness in different
experimental murine leukemia and cancer stem cell model
was strongly questioned [74]. Cancer stem cells have not
been broadly studied, so we cannot say it is valid for all
human cancers. Though this model seemingly combines
the existing knowledge in cancer biology, several questions
remain unanswered. How the self renewal in cancer stem
cells is regulated? Where the first transforming mutations
take place? What is the character played by the microen-
vironment in the cancer drama? How these genetically
unstable abnormal cells with increasing mutations survive
and proliferate? Though generally, genetic instability
should be expected to cause apoptosis as increasing
mutations should parallelly increase the overall likelihood
of cellular breakdown [89, 90]. According to clonal
selection, cancer cells carrying increasing mutations sur-
vive because they have been selected in the evolutionary
pathway [41] for their own advantageous characteristics
[39, 91]. Selection of a cell means molecular information is
conserved during replication but in cancer cells process of
replication is abnormal, and more mutations accumulate in
the next generation which implies loss or alteration of
information [32]. So it might not be realistic to say, cancer
initiates through selection of a cell or cell population.
Again, Cerny and Quesenberry [92] strongly argued that
there is no stem cell-progenitor hierarchy, rather a revers-
ible continuum of shifting chromatin and gene expression
with cell cycle transit.
Cancer metastasis
Traditionally, it is well established that metastasis occurs
when genetically unstable cancer cells adapt to a tissue
microenvironment that is distant from the primary tumor,
involving both the selection of traits that are advantageous
to cancer cells and the concomitant recruitment of traits in
the tumor stroma that accommodate invasion by metastatic
cells. It is thought that metastatic cells are selected from
genetically diverse progenitors of cancer cells [93], those
have accumulated stochastic expression of genes respon-
sible for metastasis [94] and it involves loss of cellular
adhesion, increased motility and invasiveness, entry and
survival in the circulation, exit into new tissue and eventual
colonization at a distant site [94, 95]. But genomic
instability that produces heterogeneity for selection is
directly driven by mutations [93]. We have already dis-
cussed that selection and mutation are in conceptual
opposition and it cannot be so easily said that metastatic
cells have been selected in the evolutionary pathway.
Moreover, metastatic genes have found to be expressed
early in tumor’s growth [96]. Scott et al. [97] found six
abnormal genes that were involved in both cancer initiation
and metastasis promotion. So, it may be better to see
metastasis as a fate directed by the initiation process rather
distinct event caused by the gradual changes.
Conclusions
Basic constraint in biology and medicine is the problem of
the connection between subjective and objective factors
involved in the process of life [33]. General thought is,
genomic instability initiates cancer [39], but distorted
centrosome cycle also may cause genomic instability and
cancer [98]. DNA and centrosome duplication occur in
every cell cycle [99] in coordination and determines the
normal run of cell cycle [100]. Both centrosome abnor-
malities and genomic instabilities are found early in cancer
cells [101, 102]; So it is difficult to specify one as primary.
Changes in genes such as DNMTs, MBDs, HMTs, HDACs,
and HATs, etc. are found to be responsible for character-
istic alterations in the so-called cancer epigenome [55].
Together, all these make sense that underlying process of
cancer initiation is becoming hazier for materialist
molecular biology with classical advances. After all, con-
cepts of oncogenes/tumor suppressor genes have shown
hard success to provide any convincing explanation for
cancer initiation [98], because each tumor could be dis-
tinctive in its genetic makeup and any regular set of gene
mutations cannot be accounted with malignancy [103].
Biological molecules act as both specialized chemicals and
informational molecules simultaneously. It is analogous to
a computer where chemistry corresponds to hardware and
information to software, and complete understanding of the
way of biological organization requires the explanation of
both the hardware and software aspects [104]. Cancer
might act as unprecedented and abnormal ‘whole’ (like
organs) in the complex hierarchy of ‘wholeness’ that works
in our body system (cell \ organ \ organism). This very
complex cancer phenomenon, involving so many genes and
molecules in the progression of a single tumor, seems to be
stochastic by nature, and requires thinking in a way that the
alterations are not local, rather the manifestation of the
alterations seems to be local and it might be the fact. So,
cancer initiation should be viewed from a new holistic
paradigm underlying the process of origin and function of
life.
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